mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.
Company profile
Ticker
TNFA
Exchange
Website
CEO
Howard Yeaton
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Akers Biosciences Inc, Akers Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Akers Acquisition Sub, Inc. • Bout Time Marketing Corporation • XYZ Merger Sub Inc. ...
TNFA stock data
Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
26 Jul 24
8-K
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
26 Jul 24
DEF 14A
Definitive proxy
1 Jul 24
8-K
Material Modifications to Rights of Security Holders
24 Jun 24
S-3
Shelf registration
21 Jun 24
8-K/A
Entry into a Material Definitive Agreement
20 Jun 24
PRE 14A
Preliminary proxy
20 Jun 24
8-K
Entry into a Material Definitive Agreement
17 Jun 24
D
$15.15 mm in equity / options / securities to be acquired, sold $15.15 mm, 5 investors
31 May 24
D
$26.85 mm in equity / options / securities to be acquired, sold $26.85 mm, 4 investors
31 May 24
Latest ownership filings
3
Stephen Friscia
28 Jun 24
3
Initial statement of insider ownership
30 May 24
SC 13D
PharmaCyte Biotech, Inc.
30 May 24
3
Mitchell Glass
16 May 24
SC 13G
Global X Management CO LLC
14 Feb 24
SC 13G/A
Iroquois Capital Management, LLC
14 Feb 24
4
Paul Rivard
24 Aug 23
4
Paul Rivard
18 Aug 23
4
Christopher C Chapman JR
9 Jun 23
4
Adam Kaplin
9 Jun 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 225.66 k | 225.66 k | 225.66 k | 225.66 k | 225.66 k | 225.66 k |
Cash burn (monthly) | 818.45 k | (no burn) | 3.27 mm | 1.37 mm | 637.35 k | 910.09 k |
Cash used (since last report) | 3.18 mm | n/a | 12.70 mm | 5.33 mm | 2.48 mm | 3.54 mm |
Cash remaining | -2.96 mm | n/a | -12.48 mm | -5.10 mm | -2.25 mm | -3.31 mm |
Runway (months of cash) | -3.6 | n/a | -3.8 | -3.7 | -3.5 | -3.6 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 3 |
Closed positions | 8 |
Increased positions | 0 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.29 bn |
Total shares | 5.02 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Caroline C Williams | 3.75 mm | $9.26 mm |
Mirae Asset Global Investments | 875.93 k | $1.28 bn |
Intracoastal Capital | 364.96 k | $2.21 mm |
Iroquois Capital Management | 31.18 k | $0.00 |
Parallel Advisors | 838.00 | $2.00 mm |
Sandy Spring Bank | 116.00 | $278.00 k |
Harbor Investment Advisory | 90.00 | $215.00 k |
Arvest Investments | 34.00 | $81.00 k |
Newbridge Financial Services | 34.00 | $81.00 k |
Cornerstone Planning | 1.00 | $4.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Aug 23 | Paul Rivard | Common stock | Buy | Acquire P | No | No | 1.11 | 150,000 | 166.50 k | 400,000 |
17 Aug 23 | Paul Rivard | Common stock | Buy | Acquire P | No | No | 1.1232 | 25,000 | 28.08 k | 250,000 |
News
TNF Pharmaceuticals Trades Under New Ticker "TNFA"
24 Jul 24
MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
22 Jul 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
4 Jun 24
12 Health Care Stocks Moving In Thursday's After-Market Session
30 May 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
21 May 24
Press releases
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
24 Jul 24
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
17 Jun 24
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
31 May 24